[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Heart Rhythm Clinical and Research Solutions, LLC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":133},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,69,90,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100369264","real-world-experience-of-catheter-ablation-for-the-treatment-of-arrhythmias-100369264",false,"NCT04088071","Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias","Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias Symptomatic Using Novel CARTO Technologies: REAL Registry","REAL Registry","REAL AF Cohort\n\nInclusion Criteria:\n\n* Symptomatic PAF (AF episode terminate spontaneously within 7 days) or PsAF (AF sustained beyond 7 days, but less than 365 days) subjects who, in the opinion of the investigator, are candidates for catheter ablation.\n* \\>18 years of age.\n* Will be treated with Biosense Webster Inc. ablation technologies\n* All AF ablations performed with BWI catheters are included. This includes repeat ablations where the index procedure was performed with a non-BWI catheter.\n* Able and willing to participate in baseline and follow up evaluations\n* Willing and able to provide informed consent, if applicable.\n\nExclusion Criteria:\n\n* Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan\n* Long-standing persistent AF (AF greater than one year)\n* In the opinion of the investigator, any known contraindication to an ablation procedure\n\nCORE VA Cohort\n\nInclusion Criteria:\n\n* Documented ventricular arrhythmia appropriate for catheter ablation.\n* \\>18 years of age.\n* Will be treated with Biosense Webster Inc. ablation technologies\n* Able and willing to participate in baseline and follow up evaluations\n* Willing and able to provide informed consent, if applicable.\n\nExclusion Criteria:\n\n* Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan.\n* In the opinion of the investigator, any known contraindication to an ablation procedure.","ALL","18 Years",{"count":20,"type":21},20000,"ESTIMATED","1 Year","OBSERVATIONAL","The primary purpose of this Registry is to assess procedural safety and long-term effectiveness of catheter ablations in the treatment of subjects with PAF, PsAF, and VA. The Registry will utilize real world clinical data obtained from the use of commercially available CARTO™ technologies under the authority of a health care practitioner within a legitimate practitioner-subject relationship. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term effectiveness of catheter ablation with novel technologies for arrhythmia patients.",[26,27,28],"Paroxysmal Atrial Fibrillation","Persistent Atrial Fibrillation","Ventricular Arrhythmia",[30,31],"CORE VA","REAL AF","RECRUITING","2026-07-07",{"date":35,"type":36},"2026-07-09","ACTUAL",{"date":38,"type":36},"2018-01-01",{"date":40,"type":21},"2028-12-31",{"name":42,"class":43},"Heart Rhythm Clinical and Research Solutions, LLC","OTHER",70,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100644634","bodyguardian-monitoring-for-recurrence-of-af-100644634","NCT07671677","BOdygUardian MOnitoriNg for ReCurrencE of AF","BOdygUardian MOnitoriNg for ReCurrencE of AF (BOUNCE-AF)","BOUNCE-AF","Patients must meet all the following criteria to be eligible for inclusion in the BOUNCE-AF sub-study:\n\n1. Eligible for and willing to consent for participation in DISRUPT-AF\n2. Willing to consent to the sub-study\n3. Willing to complete the post-ablation BodyGuardian wearable monitoring\n4. Willing to complete the BOUNCE AF survey\n\nClinical staff willing to consent to complete surveys must meet one of the following requirements:\n\n1. Prescribe the monitor by enrolling patients into the BodyGuardian platform.\n2. Review monitor data using the BodyGuardian platform.\n\nExclusion Criteria:\n\n1\\. Known allergy to adhesives that would contraindicate wearing BodyGuardian",{"count":54,"type":21},100,"6 Months","The DISRUPT-AF Registry is an observational, prospective, multi-center, non-randomized, real-world registry designed to obtain clinical experience with the FARAPULSE Pulsed Field Ablation (PFA) System for the treatment of atrial fibrillation (AF). The data collected for this study will be from a subset of patients enrolled in the pre-existing DISRUPT AF Registry. Additionally, patients in the Full Monitoring Arm may be approached and consented for participation in BOUNCE-AF. The post-ablation monitoring timepoints will reflect the site's standard of care (SOC), which is typically at 6- and 12-months post-ablation. Consented patients will complete 1 survey about their experience after wearing the BodyGuardian at 6-months. Clinical staff that consent will also complete a survey on their experience using BodyGuardian. The clinical staff include those that either directly prescribe the monitor, place the monitor on the patient and\u002For train the patient on the use of the monitor, or those involved in reviewing the data.",[58],"Atrial Fibrillation (AF)","NOT_YET_RECRUITING","2026-06-23",{"date":62,"type":36},"2026-06-26",{"date":64,"type":21},"2026-07",{"date":66,"type":21},"2028-04",{"name":42,"class":43},3,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100549660","safety-and-efficacy-of-workflows-of-high-volume-single-operators-in-a-laao-device-implant-procedural-day-100549660","NCT06436924","Safety and Efficacy of Workflows of High Volume Single Operators in a LAAO Device Implant Procedural Day","Safety and Efficacy of Workflows of High Volume Single Operators in a Left Atrial Appendage Occlusion Device Implant Procedural Day: SAFE HV","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Able and willing to participate in baseline and follow up evaluations for the full length of the study\n3. Clinically qualified, in the opinion of the Investigator, to receive a LAAO device\n4. Receiving a Watchman FLX™ or Watchman FLX Pro™ LAAO device as part of their plan of care\n5. Having their LAAO device implant procedure scheduled on a qualifying high-volume\\* procedure day as assessed within 2 days (≤ 2 calendar days) prior to the planned procedure date\n\n   \\*high-volume - a calendar day in which the single implanting physician schedules ≥ 8 LAAO device implant procedures, regardless of the device manufacturer\n6. Willing and able to provide informed consent\n\nExclusion Criteria:\n\n1. Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan\n2. In the opinion of the Investigator, any known contraindication to a LAAO device or implant procedure\n3. Having their LAAO device implant procedure scheduled on a day in which the single implanting physician scheduled \\\u003C 8 LAAO device implant procedures as assessed within 2 days (≤ 2 calendar days) prior to the planned procedure date",{"count":77,"type":21},678,"SAFE HV is an observational, prospective, multi-center, non-randomized study evaluating real-world clinical experience of centers where a single procedural physician schedules eight or more left atrial appendage occlusion (LAAO) device implant procedures in a single calendar day.",[80],"Atrial Fibrillation","2025-10-29",{"date":83,"type":36},"2025-10-30",{"date":85,"type":36},"2024-05-14",{"date":87,"type":21},"2026-03-30",{"name":42,"class":43},7,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},"100541003","the-long-term-safety-and-effectiveness-evaluation-of-the-qdot-micro-system-use-in-conjunction-with-visitag-surpoint-module-for-the-treatment-of-symptomatic-drug-refractory-paroxysmal-atrial-fibrillation-100541003","NCT06324201","The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.","The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO™ System Use in Conjunction With VISITAG SURPOINT™Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation","QDOT PAS","Inclusion Criteria:\n\n1. Symptomatic drug refractory paroxysmal (AF episode terminate spontaneously within 7 days) who, in the opinion of the investigator, are candidates for ablation for AF\n2. 18 years of age or older\n3. Able and willing to participate in baseline and follow up evaluations for the full length of the sub-study\n4. Willing and able to provide informed consent for this sub-study\n\nExclusion Criteria:\n\n1. Patients who have undergone catheter ablation for atrial fibrillation (PVI, roof line, posterior wall ablation...)\n2. Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan\n3. Persistent or long-standing persistent AF\n4. In the opinion of the investigator, any known contraindication to an ablation procedure",{"count":99,"type":21},250,"Observational, multi-center, non-randomized, post-market study. This is a nested sub-study of the REAL AF Registry. Consecutive symptomatic drug refractory paroxysmal atrial fibrillation (PAF) patients from the registry will be screened for enrollment, prospectively or retrospectively, to this sub-study per inclusion and exclusion criteria.",[26],{"date":103,"type":36},"2025-10-31",{"date":105,"type":36},"2024-02-27",{"date":107,"type":21},"2028-03",{"name":42,"class":43},21,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":117,"targetDuration":119,"studyType":23,"phases":4,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100567549","amplify-ep-registry-100567549","NCT06669637","Amplify EP Registry","AMP","Inclusion Criteria:\n\n* Patients who, in the opinion of the investigator, are candidates for ablation to treat atrial fibrillation.\n* Plans to undergo an ablation procedure using the TactiFlex Ablation Catheter™, Sensor Enabled™ (TactiFlex SE) manufactured by Abbott.\n* De Novo or redo AF catheter ablation procedures.\n* Able and willing to participate in baseline and all follow up evaluations.\n* 18 years of age or older.\n\nExclusion Criteria:\n\n* Enrolled in any other cardiac device clinical trial, investigational drug trial, or any other trial that may confound the results of the ablation procedure.\n* In the opinion of the investigator, any known contraindication to an ablation procedure or to any device or drug required for use during an ablation procedure as assessed by the investigator.",{"count":118,"type":21},1100,"12 Months","An observational, prospective, multi-center, non-randomized registry designed to obtain real world clinical experience with the TactiFlex Catheter Ablation system in the treatment of Atrial Fibrillation. Patient assessments will occur at pre procedure and procedure, and 1 year post ablation",[80],[123,124],"Ablation","Radiofrequency","2024-10-30",{"date":127,"type":36},"2024-11-01",{"date":129,"type":21},"2024-11-22",{"date":131,"type":21},"2026-12",{"name":42,"class":43},""]